HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David Krugh Selected Research

Hematologic Neoplasms (Hematological Malignancy)

11/2009Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David Krugh Research Topics

Disease

1Multiple Myeloma
02/2010
1Graft vs Host Disease (Graft-Versus-Host Disease)
11/2009
1Infections
11/2009
1Hematologic Neoplasms (Hematological Malignancy)
11/2009

Drug/Important Bio-Agent (IBA)

1thymoglobulinFDA Link
11/2009
1Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
11/2009

Therapy/Procedure

1Stem Cell Transplantation
02/2010
1Drug Therapy (Chemotherapy)
02/2010
1Transplantation
11/2009
1Homologous Transplantation
11/2009